Some of the gadolinium based contrast agents are shown to produce enhancements on T1-weighted images long after their administration in certain brain structures in humans, raising questions about the safety of these agents. The enhancement is thought to be due to dechelation of the contrast agents. Understanding the pathophysiological effects requires systematic pre-clinical studies. As a first step towards this goal we conducted longitudinal in vivo studies in rodents administered Magnevist and Omniscan for ten days to quantify the temporal profile of enhancement using relaxometry and investigate if this enhancement has an effect on the tissue microstructure. Our results show that Ominiscan lowers both T1 and T2 starting from week 2 post contrast administration. However, such changes were not observed in Magnevist and saline treated animals. The contrast agents do not appear to have significant effect on any of the DTI measures.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Keywords